Key features and details
- Sensitivity: 10 ng/ml
- Range: 10 ng/ml - 1000 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Quantitative
- Reacts with: Human
Product nameIpilimumab ELISA Kit
See all Ipilimumab kits
Intra-assay Sample n Mean SD CV% Overall < 15% Inter-assay Sample n Mean SD CV% Overall < 15%
Sample typeSerum, Plasma
Range10 ng/ml - 1000 ng/ml
Sample specific recovery Sample type Average % Range Serum 85% - 115%
Assay durationMultiple steps standard assay
Species reactivityReacts with: Human
Note: Ipilimumab ELISA kit ab237653 is intended for Research Use Only, not for use in diagnostic procedures.
This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Ipilimumab in the sample or standard. Results of samples can be determined directly using the standard curve.
Storage instructionsStore at +4°C. Please refer to protocols.
Components 96 tests Assay Buffer 2 x 50ml HRP-conjugate Probe 1 x 12ml Ipilimumab Standard S1 1 x 0.3ml Ipilimumab Standard S2 1 x 0.3ml Ipilimumab Standard S3 1 x 0.3ml Ipilimumab Standard S4 1 x 0.3ml Ipilimumab Standard S5 1 x 0.3ml Ipilimumab Standard S6 1 x 0.3ml Ipilimumab Standard S7 1 x 0.3ml Micro ELISA Plate 1 unit Plate sealers 2 units Stop Solution 1 x 12ml TMB substrate 1 x 12ml Wash buffer (20X) 1 x 50ml
RelevanceIpilimumab is a fully human IgG1 kappa antibody that binds to CTLA-4 (cytotoxic T lymphocyte associated antigen 4), a molecule on T cells that is indicated for unresectable or metastatic melanoma. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells. The proposed mechanism of action is indirect, and may be through T-cell - mediated anti-tumor immune responses.
ab237653 has not yet been referenced specifically in any publications.